UroToday.com
@urotoday
Largest global online community of #urological medical professionals & patients. #bladdercancer #menshealth #prostatecancer #kidneycancer #Urology
#CREST Trial: Sasanlimab immunotherapy + BCG in BCG-naive #BladderCancer. Sam Chang, MD, MBA @VUMCurology joins @zklaassen_md @GACancerCenter to discuss this three-arm study of over 1,000 patients showing a remarkable 32% reduction in event-free survival events with the…
Radiation vs systemic therapy for isolated pelvic recurrence after cystectomy. @AndreaNecchi & Comron Hassanzadeh join @UroDocAsh in a debate about optimal management of isolated pelvic recurrences after radical cystectomy. #WatchNow on UroToday > bit.ly/45e2hPP
Efficacy of TAR-200 in NMIBC: 1-Year Outcomes. Joseph Jacob, MD, MCR @UpstateNews joins @UroDocAsh @MDAndersonNews to discuss the #SunRISe trial durability data for TAR-200, a sustained-release gemcitabine device for BCG-unresponsive high-risk non-muscle invasive bladder cancer…
Adjuvant pembrolizumab shows sustained survival benefit in #RenalCellCarcinoma at 5 years. Naomi Balzer-Haas, MD @PennMedicine joins @PBarataMD @caseccc to discuss the #KEYNOTE564 trial, showing sustained overall survival benefit with adjuvant pembrolizumab in clear cell #RCC.…
Stay up-to-date on #microhematuria guidelines! @DanBarocas @VUMCurology and @zklaassen_md @GACancerCenter break down the latest 2025 @AmerUrological recommendations for diagnosis & treatment. Watch now & enhance your practice > bit.ly/3GWhLyh #Urology #BladderHealth…
Multimodal deep learning predicts #BladderCancer response to neoadjuvant chemotherapy. @FaltasLab @WeillCornell joins @UroDocAsh @MDAndersonNews to discuss a deep learning model for predicting pathologic complete response to neoadjuvant chemotherapy in #MIBC. #WatchNow >…
#STELLAR002 Trial: Zanzalintinib combo shows promise in clear cell #RCC. @JadChahoud @MoffittNews sits with @PBarataMD @caseccc discussing zanzalintinib combinations in first-line clear cell renal cell carcinoma. Dr. Chahoud explains the study's design, testing two arms:…
Recombinant BCG phase I/II trial addresses #BladderCancer treatment shortage - @JoshMeeks @NUFeinbergMed sits down with @UroDocAsh @MDAndersonNews to discuss the potential of recombinant BCG in a phase I/II trial. Watch to learn more about this innovative approach >…
Intratumoral heterogeneity drives therapy resistance in metastatic #ProstateCancer. @laurasenamd @hopkinskimmel joins @AndreaMiyahira @PCFnews discussing a detailed analysis of a patient's disease progression over seven years, Dr. Sena demonstrates how distinct cancer cell…
Circular RNA RMST drives neuroendocrine transdifferentiation in #ProstateCancer. Housheng Hansen He, Mona Teng & Xin Xu join @AndreaMiyahira to discuss their @Cancer_Cell paper revealing circular RMST as essential for neuroendocrine tumor growth. From REST loss to ASCL1…
#ONECUT2 crystal structure reveals potential for targeted #ProstateCancer therapy. @DrGallent @CedarsSinai joins @AndreaMiyahira @PCFnews presenting work revealing the first crystal structure of ONECUT2, showing how its CUT and HOX subdomains function together to create…
BMS-986365: targeting AR degradation and antagonism in metastatic #ProstateCancer. Manish Patel, MD sits down with @PBarataMD to discuss BMS-986365 — a dual AR degrader and antagonist showing promising PSA responses in pretreated pts. 💊 Deeper AR inhibition 🧬 Active in AR WT &…
Treatment options for de novo metastatic hormone-sensitive #ProstateCancer. @neerajaiims @huntsmancancer joins @zklaassen_md @GACancerCenter in a case-based discussion Dr. Agarwal emphasizes the importance of treatment intensification beyond ADT monotherapy, which remains…
Clinical trial access barriers for Veterans with #ProstateCancer. @MadisonKrischak @UMichUrology joins @zklaassen_md @GACancerCenter to discuss major gaps in VA trial participation: 🔹 Only 6% of trials included VA sites 🔹 <50% of VA facilities ever enrolled 🔹 Vast…
ctDNA in #BladderCancer: Prognostic value and ongoing clinical trials. @DrRosenbergMSK @MSKCancerCenter & @PGrivasMDPhD @fredhutch join @UroDocAsh @MDAndersonNews to discuss on UroToday. 🧬 ctDNA in bladder cancer: promising but not practice-changing—yet. They explain that…
Pre-cystectomy ctDNA levels and metastatic recurrence in #BladderCancer patients. @ReubenBenDavid1 @IcahnMountSinai joins @zklaassen_md @GACancerCenter to discuss new research using Signatera to quantify ctDNA—not just detect it. 🔹 3 risk groups 🔹 Median progression: 5–12 mo…
Histopathologic features and transcriptomic signatures do not solve the issue of magnetic resonance imaging-invisible #ProstateCancers: a matched-pair analysis. #ProstateCancer invisibility on mpMRI ≠ indolence! A matched-pair study found no histopathologic or transcriptomic…
#TRITON3 subgroup analysis: Rucaparib benefits BRCA+ patients with liver mets. David Morris, MD, FACS @UA_Nashville joins @zklaassen_md @GACancerCenter explaining that TRITON3 studied rucaparib vs physician's choice (docetaxel or AR-switch therapy) in men with BRCA1/2 or ATM…
This week on the Prostate Health Show, experts Dr. Stacy Loeb and Dr. Rana McKay, Medical Oncologist and Professor of Medicine and Urology at @UCSanDiego, discuss #prostatecancer clinical trials. Tune in live on SiriusXM, Channel 110, on July 23 at 6:30 p.m. ET.
Sasanlimab combined with BCG for high-risk non-muscle invasive #BladderCancer. @MattGalsky @TischCancer joins @UroCancerMD @VUMCurology to discuss findings from the CREST trial, examining the addition of immune checkpoint blockade to BCG in BCG-naïve #NMIBC. #WatchNow >…